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1. Introduction 
Hematopoietic stem cell transplantation (HSCT) has been used to cure many pediatric 
patients with both malignant and non-malignant diseases in whom conventional therapy 
has failed. HSCT is generally performed after the administration of high sublethal doses of 
chemotherapy or chemoradiotherapy to achieve myeloablation, immunosuppression and 
eradication of abnormal cells. The use of high dose cytotoxic therapy before HSCT places 
children at risk for acute and  long-term side effects which may differ or be more severe 
than those seen in children who did not receive HSCT.  One important organ that may be 
damaged from cytotoxic therapies used to treat recipients of HSCT has been the brain.  
Survival rates for childhood ALL improved after the introduction of treatments to prevent 
the development of central nervous system (CNS) leukemia. During the past 25 years, CNS 
prophylaxis for leukemia has consisted of either intrathecal chemotherapy alone or a 
combination of both chemotherapy and cranial irradiation. There is a wide range of deficits 
associated with this CNS prophylaxis. Neurological sequelae include severe 
leukoencephalopathy to more subtle and mild dysfunction, such as learning disorders and 
abnormalities that can be seen on CT scan or MRI (Packer R 1986, Brouwers P 1985). 
In contrast, patients with malignant brain tumors often present with neurological symptoms 
of their primary disease such as a) increased intracranial pressure b) problems with balance 
and cranial nerve findings, which are associated with infratentorial tumors and  c) seizures, 
which are often seen in those with supratentorial tumors. The treatment of malignant brain 
tumors involves chemoradiotherpay in addition to neurosurgery. The cranial irradiation 
that these children receive is often more than double that received by patients with acute 
leukemias. Therefore, the neurological sequelae of patients with this particular malignancy 
are greater than that seen for patients with a hematological malignancy.  
The neurocognitive sequelae following cranial irradiation and chemotherapy for childhood 
acute leukemia and brain tumors have been well documented  (Fletcher et al 1988, Smibert  
et al 1996, Anderson et al 1997, Stehbens et al 1991, Butler  and Copeland 1993, Moleski  
2000, Ris  and Noll  1994, Mulhern and Butler 2004). However, information regarding the 
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impact of HSCT and the neurocognitive function of HSCT recipients is still emerging, 
especially among patients with genetic diseases and those who have a primary immune 
deficiency.  
The different types of transplants and their complications can add to the neurological 
complications that follow HSCT. In general, there are three different types of HSCT: 1) 
autologous, which is used for the treatment of solid tumors and lymphomas, 2) syngeneic 
and 3) allogeneic, which is used for the treatment of leukemias, genetic diseases and 
immunodeficiencies.    
In this chapter we review both the acute neurological complications that can occur following 
HSCT and the long-term clinical significance of these complications, especially the 
neurocognitive outcomes of this therapy.  
2. Neurological sequelae following HSCT 
Neurological complications following HSCT have not been studied well, especially in the 
pediatric population. The majority of studies have focused upon adult patients A 
prospective study of 180 adult HSCT patient autopsies  (177 allogeneic and 3 autologous) 
detected neuropathologic abnormalities in over 90% of the subjects (Bleggi-Torres et al,  
2000). The most frequent findings in this study were subarachnoid hemorrhage (32%), 
intraparenchymal hemorrhage (27%) and fungal infections (9%). There were no abnormal 
findings in 9% of the autopsies.  A smaller series of autopsy studies showed similar findings 
(Mohrmann et al, 1990). Although there were a high number of patients with nervous 
system involvement following HSCT, we do not know if these findings led to clinically 
significant neurological complications.  
The incidence of clinical neurologic symptoms varies from 10-40%. Weber et al evaluated 
165 pediatric patients following HSCT. Of these patients, 67% were allogeneic and 33% were 
autologous. Of these 165 patients, 24% developed neurologic complications. The cause of the 
neurological complications included: infections (n=10), drug toxicity (n= 5), cerebrovascular 
events (n=2), and CNS relapse (n=2). Among the infections, aspergillus and toxoplasmosis 
were the most frequent pathogens isolated (Weber et al, 2008).  
A study of patients with Hodgkin Disease who received an autologous HSCT showed early 
symptoms of neurological complications such as encephalopathy, seizures, cerebral 
hemorrhage and psychiatric symptoms (Snider et al, 1994). A separate study of a similar 
population showed the incidence of clinically significant neurological complications as 
being 3.2%. (Guerrero et al, 1999).  
The incidence of neurological symptoms varies depending upon 1) the disease and the 
therapies used to treat that disease prior to HSCT, 2) type of transplant (autologous, 
syngeneic and allogeneic and the complications associated with the specific type of 
transplant  3) conditioning therapy (chemotherapy alone versus chemoradiotherapy,  4) 
immunosuppressive therapies and 5) the infections that may occur from being 
immunosuppressed.   
3. Impact of disease  
There are various reasons for patients to receive HSCT. Among the common diseases 
include a) hematological malignancies such as acute leukemia,  b) malignant solid tumors 
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such as brain tumors and c) nonmalignant diseases such as genetic diseases, immune 
deficiencies and hemoglobinopathies.  All of these diseases can have an impact on the 
neurological outcome of patients, even without a transplant.  
Leukemia patients who are either high-risk patients or have CNS disease, often receive 
between 1800 or 2400 cGy cranial irradiation for the prophylaxis or treatment of CNS 
leukemia. Many believe that the threshold between 1400 and 1800 cGy does not have an 
impact upon neurocognitive function. However, it is known that therapies greater than 1800 
cGy appear to affect the neurocognitive function of leukemia patients. In contrast, patients 
with brain tumors, often receive cranial radiation that can be more than twice that 
traditionally given in the treatment of ALL.  Despite differences in the therapy, there are 
similar declines that are seen in the neurocognitive function of both groups of patients, 
especially those who are young at diagnosis.  
For patients with non-malignant diseases, the pre-transplant neurological sequelae are often 
related to the disease. For example, patients with sickle cell disease often have a history of 
strokes prior to HSCT, this can impact a patient’s neurological status prior to coming to 
transplant. In addition, patients with hemoglobinopathies who are on hypertransfusion 
protocols, may have evidence of iron overload that may involve the brain.  Patients with 
genetic diseases such as adrenoleukodystrophy (ALD) and Krabbe’s disease often have 
disease specific neurological findings prior to HSCT. These patients have lesions in their 
CNS that can affect both the motor and mental development of these patients. Although 
there may be some improvement following HSCT, in general these changes do not resolve 
completely.   
Patients with immunodeficiency, such as severe combined immunodeficiency (SCID) or 
Wiskott Aldrich Syndrome, often have had serious life threatening infections prior to their 
diagnosis, which may impact their overall neurological function. Therefore, it is important 
to assess patients both before and after HSCT to really understand the impact of HSCT upon 
neurological function. 
4. Impact of type of transplant 
Patients who receive an allogeneic transplant are thought to have increased neurologic 
side effects compared to those receiving an autologous transplant. However, a 
retrospective study of 425 (mostly adult patients) found that the incidence of neurologic 
complications was similar in both autologous and allogeneic patients (Saiz et al , 2004). 
The complications that were seen varied depending upon the type of disease and type of 
transplant. For example, patients with Acute Myelogenous Leukemia (AML) receiving an 
autologous transplant developed more subdural hematomas due to prolonged 
thrombocytopenia; whereas, patients with central nervous system (CNS) infections were 
more common in those receiving an allogeneic transplant due to prolonged 
immunosuppression.   
Allogeneic transplant recipients are vulnerable to developing graft versus host disease 
(GVHD).  The risk is greatest among patients receiving an unrelated transplant despite the 
stem cell source. There has been one report of possible central nervous system GVHD in two 
patients. Two patients developed hemiparesis, seizure, encephalopathy and MRI findings of 
hyperintense white matter lesions on T-2 weighted images. A brain biopsy on one patient 
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and an autopsy finding on the other revealed perivascular lymphocytic infiltrates of 
primarily donor origin. It is difficult to make an unequivocal diagnosis of this entity, since 
there are a number of other etiologies that may explain these findings. However,  physicians 
should be made aware of this possibility (Kamble, et al,  2007). 
The source of stem cells may also affect the neurologic outcomes. There are three different 
sources of stem cells: bone marrow, cord blood and peripheralb blood stem cells. Patients 
who receive peripheral blood stem cells often have a delay in platelet recovery, thus 
increasing the risk of subdural hematomas. Alternatively, patients with cord blood 
transplants can have delayed engraftment, thus increasing the period of neutropenia or 
thrombocytopenia. This can either increase the risk of infections or increase the chances of 
CNS bleeding, both of which can increase neurologic complications.   
Neurologic complications have also been reported following the infusion of stem cells. In 
one report of 179 consecutive patients, 3 developed complications following the infusion  of 
cryopreserved stem cells (Hoyt et al, 2000). The symptoms were global amnesia (n=1), 
cerebral infarction (n=2). The patients who developed infarcts showed evidence of a cerebral 
hemorrhage due to thrombocytopenia and the other showed cerebral aspergillus on 
autopsy. Therefore, although there are sporadic reports of complications due to the infusion 
of cells, the risk of the stem cell infusion itself is very low.  
5. Impact of conditioning therapy 
Ther pretransplant conditioning therapy consists of either high doses of chemotherapy or 
total body irradiation (TBI). The high dose chemotherapy often crosses the blood brain 
barrier and the TBI has a direct cytotoxic effect upon the brain. This pretransplant 
conditioning regimen and the therapy used for the prophylaxis against graft versus host 
disease (GVHD) are thought to be responsible for the majority of neurological complications 
following HSCT. The use of various chemotherapy regimens and the use of TBI vary 
depending upon the type of disease that is being transplanted. For example, patients with 
nonmalignant disorders are often treated with high dose busulfan while most patients with 
acute lymphoblastic leukemia are treated with TBI in addition to a chemotherapeutic agent. 
All agents can produce some acute neurotoxicities and may even have some late onset 
neurotoxicities. The most common agents that are used in transplant conditioning regimens 
and their side effects are shown in Table 1.  
The impact of the conditioning regimen generally affects the patients during the first 30 
days post-HSCT, or the acute post-transplant period. Complications during this time period 
include pancytopenia, metabolic abnormalities, coagulopathies, drug toxicities and 
infections due to neutropenia. During this period, subdural hematomas are common due to 
thrombocytopenia and /or platelet refractoriness. Many patients also develop endothelial 
cell damage from alkylators such as cytoxan. This may also increase patient’s risk of 
developing subdural hematomas. Intraparenchymal hemorrhages are less common, but may 
occur as well. These are usually associated with myeloid leukemias.  
During the acute period, patients are severely neutropenic. As a result, HSCT recipients are 
at risk of developing a variety of infections they include bacterial, viral and fungal 
infections.  Table 2 details the most common neurologic complications that occur post-
HSCT. 
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Drug Neurologic Toxicities 
Busulfan  Reversible encephalopathy with somnolence, confusion, 
decreased alertness, myoclonus, headaches and 
hallucinations. Seizures in approximately 10% of patients. 
Prophylactic use of antiepileptics is recommended. (De La 
Camara et al 1991 and Vassal et al 1990) 
Carboplatin Ototoxicity in over 80% of children with neuroblastoma 
(Parsons et al 1998) 
Carmustine Optic disc and retinal microvaculopathy with variable degrees 
of visual loss.  Very high doses 9> 1,500 mg/ m2) can be 
associated with severe irreversible encephalopathy (Johnson 
et al 1999, Burger et al 1981) 
Cytarabine arabinoside Pancerebellar syndrome+/- diffuse encephalopathy with 
lethary, confusion, and seizures (Baker et al 1991) 
Etoposide  Acute confusional state, somnolence, and seizures, which 
resolve spontaneously (Leff et al 1988) 
Ifosphamide Encephalopathy with lethargy, confusion and seizures in 10-
40% of patients. Visual or auditory hallucinations, myoclonus, 
or muscle rigidity have been reported, which is usually self 
limited, but have been reported to progress to a coma. (Pratt  
et al 1990,   DiMaggio et al 1994) 
Thiotepa Chronic encephalopathy with progressive declines in 
cognitive and behaviorial function 
 
Table 1. Neurologic Toxicity of Commonly Used Drugs in HSCT Conditioning Regimens 
One of the major complications of CNS therapies is the development of  methotrexate 
induced leukoencephalopathy. The dose of intravenous methotrexate (not intrathecal 
methotrexate) correlates with the development of leukoencephalopathy. The incidence of 
this phenomenon is 16-69%. Patients may have no neurological symptoms. Methotrexate 
induced Leukoencephalopathy does not progress to progressive multifocal 
leukoencephalopathy ((Knaap et al 2005, Pande et al 2006, Reddick et al 2005). 
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 < 30 days 30-100 days > 100 days 
Infections Fungus (aspergillus,candida, etc) → →  →→→→ 
 Virus (HHV6  and CMV) Herpes Zoster  
  Toxoplasmosis PML (JCV) 
 Gram negative 
bacteria 
Gram + bacteria Encapsulated bacterial 
infections 
 
Drug induced 
neurotoxicity 
1) Cyclosporine  or 
tracrolimus 
induced 
encephalopathy 
(PRES)   
2) Methotrexate 
encephalopathy 
3) Chemotherapy 
related side effects 
 
→ Multifocal  
leukoencephalopathy 
 
   
Vascular 
complications 
1) Subdural 
hemorrhage,  
2) intracranial 
hemorrhage,  
3) thrombotic 
disease 
  
Post-HSCT    1) Post-transplant 
lymphoproliferative 
disease,  
2) relapse or 
3) secondary malignancy 
Causative issue Neutropenia Acute GVHD  
and deficiency of 
cellular 
immunity 
Chronic GVHD and 
deficiency of both cellular 
and humoral immunity 
Table 2. CNS complications following HSCT 
Progressive multifocal leukoencephalopathy is a more devastating complication  that is 
differentiated from methotrexate induced leukoencephalopathy by the presence of more 
extensive areas of white matter disease. Approximately 7% of patients who receive cranial 
irradiation and/ or intrathecal chemotherapy prior to HSCT and intrathecal methotrexate 
following HSCT develop progressive leukoencephalopathy 4-5 months post-HSCT. Clinical 
manifestations of this problem include dysarthria, confusion, seizures, upper motor neuron 
www.intechopen.com
 
Neurologic Sequealae of Hematopoietic Stem Cell Transplantation (HSCT) 
 
523 
weakness and coma. Leukoencephalopathy is usually chronic and often fatal.  (Bleyer, 1981, 
Thompson et al, 1986).  Leukoencephalopathy with severe neurological sequelae and death 
have also been attributed to amphotericin B following TBI in transplant recipients (Devinsky 
et al, 1987). Figure 1 shows the presence of progressive multifocal leukoencephalopathy in 
an 18 year old patient with ALL in 3rd remission 4 months following an unrelated BMT. The 
patient had received 1800 cGy of cranial irradiation prior to HSCT for the treatment of his 
ALL and received 1360 cGy of TBI as part of his HSCT conditioning regimen. The patient 
developed seizures and confusion and subsequently went into a coma. Lumbar puncture 
did not reveal any infectious etiology. The MRI shows extensive white matter changes 
consistent with progressive multifocal leukoencephalopathy.   
 
 
Fig. 1. An 18 year old male with ALL in 3rd remission following an unrelated bone marrow 
transplant. His conditioning regimen consisted of TBI 1360cGy. Four months post-HSCT he 
developed seizures and a coma.. An MRI of his head showed bilateral lesions in the deep 
subcortical white matter of the temporal lobes. The MRI findings are consistent with 
progressive multifocal leukoencephalopathy 
Many patients are unable to tolerate the intensive chemotherapies that are used in 
myeloablative transplants. Thus many centers have begun to employ the use of reduced 
intensity conditioning regimens (RIC). RIC often results in increased GVHD, which may 
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also increase the neurological sequelae and this may negate the beneficial long term effects 
that would be seen of decreased drug toxicity. Although it is expected that a RIC will have 
fewer neurological complications, there are no studies that have been completed in this area. 
6. Impact of immunosuppression 
Patients are often very immunosupressed following HSCT. A variety of complications can 
occur due to immunosuppression.  The second period of transplantation occurs during the 
time between 30-100 days. During this period, patients may develop GVHD, due to 
alloreactive donor derived T cells from the graft attacking nonshared recipient alloantigens 
in target tissues such as the skin,  liver and GI tract. During this time, radiation given during 
the conditioning period damages the host tissue from the mucosa, liver and other tissues. 
Activated cells from the damaged recipient tissues secrete inflammatory cytokines, which 
upregulate expression of recipient antigens. Presentation of recipient antigens to donor T 
cells occurs and subsequent proliferation and differentiation of these activated T cells occurs 
during this time. Activated CD4+ T cells expand and generate cytokines promote 
differentiation of CD8+ T cells to cytotoxic T cells, which kill recipient cells and cause 
further tissue damage.  
In order to prevent GVHD, patients are often treated with either Cyclosporin A (CSA) or 
tacrolimus. Both of these agents can cause neurotoxicity. The most frequent complications 
seen in patients receiving these agents  are tremors (40%), paresthesias ( 11%)  [Walker et al 
1988]. Approximately 5% of patients develop isolated seizures. Both of these agents can also 
cause posterior reversible encephalopathy (PRES syndrome).  The pathogenesis of PRES is 
unclear. However, both of these agents disrupt the blood brain barrier or interfere with 
cerbrovascular autoregulation, resulting in vasogenic edema. This process can rarely 
progress to irreversible cytotoxic edema (Hinchey et al  1996, Schwarz et al 1995, Mckinney 
et al 2007). Patients who develop this syndrome develop headache, confusion, blurry vision, 
visual hallucinations, seizures and motor dysfunction.  MRI findings include white matter 
edema which usually affects the parietal-occipital regions symmetrically  and is best seen on 
fluid- attenuated inversion recovery (FLAIR) sequences. PRES can occur despite normal 
drug levels. The symptoms of this condition resolve after discontinuation of the drug. The 
development of PRES does not preclude the safe use of the alternate agent and patients have 
frequently switched back and forth.   
Many HSCT recipients are on corticosteroid therapy, which can also lead to neurological 
complications. One of the major side effects of corticosteroid therapy includes steroid-
induced myopathy, which can occur early in therapy. Steroid-induced myopathy is often 
characterized by proximal muscle weakness, usually in the hip and neck flexors. 
Discontinuation of corticosteroids will improve the condition, but that may take many 
months to achieve. Corticosteroids are also well known to cause a number of psychiatric 
symptoms such a hallucinations, insomnia, anxiety, mood swings and memory problems. 
After one hundred days post-HSCT, chronic GVHD may occur.  The immune system 
generally tends to recover, however if chronic GVHD occurs, there tends to be a 
prolongation of both cellular and humoral recovery. Patients are at high risk of developing 
infections with a variety of infections that can include bacterial, viral and fungal infections. 
Since HSCT recipients are on anti-inflammatory medications such as corticosteroids, it may 
be difficult for patients to display the classic signs of CNS infections such as fever and 
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meningismus. In addition, many patients have other ongoing complications from their 
transplant that CNS infections are not often considered.  
Patients with CNS infections can be grouped into those who have nonfocal generalized CNS 
dysfunction such as headaches and meningismus or into those with focal findings 
suggestive of a mass lesion or stroke. In the first month following HSCT, most patients are 
neutropenic and are at risk of bacterial infections.  In the first month following transplant, 
gram negative bacterial infections are more predominant, but in the later period (30-100 
days) of HSCT, gram positive infections predominate. Methicillin-resistant Staphylococcus 
aureus or epidermidis (MRSA/ MRSE) and Listeria monocytogenes may cause meningitis, 
encephalitis and ventriculitis.  
Viral infections post-HSCT include those who develop adenovirus or Coxsackie virus B4 
can also produce encephalitis (Krouwer et al 2003, Cree et al 2003). Acquired viral 
infections such as with human herpes virus 6 (HHV6) and  cytomegalovirus (CMV) 
infections are also common during this period.  Most children develop primary HHV6 
infection between 6 months and 5 years of age (Yoshikawa et al  2003, Gorniak et al 2006). 
After the primary infection, this virus remains latent in the body and reactivates upon 
immunosuppression of the host. HHV6 often reactivates concurrently with GVHD and 
can develop in approximately 28%-78% of HSCT recipients (Yoshikawa et al 2003, 
Gorniak et al 2006). Symptoms that have been associated with CNS HHV6 infections 
include short-term memory loss, mental status changes, fever and headache.  The 
mortality of HHV6 infections is greater than 50%. Figure 2 shows the MRI of a 14 year old 
female patient with ALL and chronic GVHD. 2 months following HSCT she developed  
fevers, headaches, seizures and confusion. A CT scan was read as normal, however the 
MRI showed hyperintensity in the limbic system. A lumbar puncture revealed HHV6 
infection and she was treated with foscarnet. This patient recovered from her HHV6 
infection, however the mortality of this infection is more than 50% (Yoshikawa et al 2003, 
Gorniak et al 2006).  
Most pediatric patients have indwelling central venous catheters during their transplant. 
These patients are at risk of developing fungal infections due to Candida. Candidemia can 
become disseminated and involve the CNS with septic emboli. Aspergillus infections are the 
most common fungal infection following HSCT. These often occur when patients are either 
neutropenic or when their T cells have not recovered (day 0-100). MRI findings of patients 
with Aspergillus often show ring enhancing lesions that may have hemorrhage surrounding 
the lesion. Aspergillus preferentially occurs in the basal ganglia, cerebral hemispheres, and 
the corpus callosum.   Unfortunately, a biopsy of this area is very difficult and treatment is 
often started empirically.  The treatment is usually liposomal amphotericin, which may add 
to neurological complications post-HSCT. There are newer agents that are also available for 
the treatment of aspergillus. The mortality of cerebral aspergillosis approaches 85-100% 
depending upon the degree of neurological compromise at presentation (Guermazi et al  
2003, Miaux et al 1995).   
The most common parasitic infection following HSCT is Toxoplasma gondii. Patients present 
with focal symptoms and mild to severe encephalopathy. MRI findings on these patients 
show the presence of multiple mass lesions affecting the basal ganglia with minimal to no 
enhancement. Patients who have not received prophylactic antibiotics with trimethoprim 
sulfamethoxazole are at risk of developing this infection.  
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Fig. 2. An MRI of a 14 year old female with ALL in 3rd remission following an unrelated 
cord blood transplantation. She developed severe graft versus host disease fever, confusion 
and  seizures. A lumbar puncture revealed the presence of HHV6. Flair T2 demonstrates 
biparietal white matter increased signal intensity more on the left side. This is consistent 
with HHV6 lesion.  
Finally, post-transplant lymphoproliferative disease (PTLD) covers a spectrum that involves 
benign polyclonal lymphoid hyperplasia to malignant monoclonal lymphoma. Often Ebstein 
Barr Virus (EBV) is the infectious etiology of the malignant lymphoma. In children, the risk 
is related to a primary EBV infection in a previously seronegative younger patient (Newell 
et al, 1996). These patients are usually treated with either reduced immunosuppression or 
chemotherapy. When PTLD does involve the CNS, the prognosis is poor. 
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7. Neurocognitive function following HSCT 
The potential impact of the disease, intensive therapy, social isolation and altered family 
dynamics in a young child is uncertain and cannot be studied well in pediatric patients. Pot-
Mees (1989) documented the profound psychosocial effects of HSCT on patients and 
families. Recipients of HSCT, despite the underlying disease for which they are 
transplanted, often face prolonged periods of time in the hospital. Many do not attend 
school on a regular basis. During the time that they are receiving therapy, they often have 
some malnutrition due to nausea and vomiting from the therapy to treat their underlying 
disease. Even after their therapy is completed, some children have an adaptive school 
program. After HSCT, many children do not have a normal immune system for a long 
period after HSCT. As a result, they are not involved with extracurricular activities like 
other age-matched peers.  
One would expect that HSCT would increase the neurocognitive deficits seen in pediatric 
leukemia survivors. The current studies of neurocognitive functioning upon HSCT 
recipients have yielded mixed results. Most studies of neurocognitive function upon HSCT 
recipients contain patients with all diseases (malignant and non-malignant), varying types 
of transplants and conditioning regimens and different age groups. This makes it difficult to 
interpret the impact of HSCT upon specific disease groups.  
Some studies have shown no significant differences in intellectual functioning  in patients 
who are pre-HSCT versus those who are one-year post-HSCT evaluations, except for those 
patients who have been younger at diagnosis (Kaleita et al 1989, Kramer et al 1992, Simms et 
al 1998, Phipps et al 1995, Simms et al 2002, Phipps et al  2000, Chou et al 1996, Phipps et al 
2008). Whereas, other  studies have reported that those patients who receive cranial 
irradiation have declining neurocognitive function in terms of IQ, achievement, memory 
and fine motor skills (Cool et al 1996, Smedler et al 1995, Said et al ,  Kramer et al 1997, Shah 
et al 2008).  
Consistently, all of these previous studies have shown that a younger age at diagnosis and 
treatment have resulted in significant declines in neurocognitive function In addition, 
deficits in fine motor skills appear to be more pronounced in HSCT recipients who received 
cranial irradiation at a younger age than those who received cranial irradiation at an older 
age (Phipps 2000, Cool 1996, Smedler 1990). Since cranial irradiation appears to affect the 
information processing, memory and attention mechanisms of the brain, patients who have 
received cranial irradiation (brain tumor patients and those who had CNS leukemia or 
received propylaxis for CNS leukemia) are at particular risk of developing long-term 
cognitive deficits.  
Phipps et al conducted the largest pediatric trial relating to the neurocognitive function of 
patients post-HSCT. This prospective study had 102 patients, who received a full battery of 
tests for up to 3 years post HSCT. In this study, the neurocognitive function (cognitive and 
academic functioning) was not impacted by HSCT in patients greater than 6 years of age. 
There was no impact of TBI upon neurocognitive function.  The greatest decline in 
neurocognitive function occurred in those < 3 years of age.  A follow up study done in 2008, 
increased the population being evaluated to 268 patients. Although the majority of patients 
had a malignant disease, there were minimal neurocognitive delays. There were subgroups 
of patients that were increased risk of neurocognitive delays. These subgroups included 
those who received TBI, recipients of unrelated transplants, and those who developed graft 
versus host disease (Phipps et al 2008).  
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For patients who received HSCT for genetic diseases of immunodeficiencies, the information 
regarding neurocognitive function post-HSCT is sparser. Most patients with genetic disease 
have problems due to their underlying disease. Following HSCT, the developmental 
outcomes vary depending upon the disease that they were transplanted for and their pre-
HSCT performance scores. Prasad et al transplanted 159 pediatric patients with a variety of 
inherited metabolic disorders.  Among patients with  MPS I (Hurler’s Disease), most  have 
shown continued increases in their neurocognitive skills, with 81% of them being in age 
appropriate classes. However, for patients with MPS III (Krabbe’s disease), there was less of 
an impact of HSCT upon neurocognitive function. Most children with Krabbe’s disease have 
severe neurological complications of this disease. Of the surviving patients with Tay-Sachs, 
there was no impact of HSCT upon their neurocognitive function and the surviving patients 
are severely debilitated (Prasad 2008).  
There have not been any formal studies upon the neurocognitive function of patients with 
hemoglobinopathies following HSCT.  Walters et al recently reported the outcomes of 
patients receiving HSCT for sickle cell disease. In that study of  55 long-term survivors of 
histocompatible HSCT, 19 patients developed neurological complications post HSCT, which 
consisted primarily of seizures. One patient had graft rejection and subsequently developed 
a second thrombotic stroke. However, no formal neurocognitive testing was done on these 
patients to determine the long-term clinical impact of transplant on this group of patients 
(Walters et al, 2009).   
Many patients with immunodeficiencies, present to a doctor only after they have had a life-
threatening illness. Since these children are very young at diagnosis, they are usually 
socially isolated after the diagnosis is made. They are not exposed to their age-matched 
peers. In addition, they often have a history of chronic infections, especially their respiratory 
systems.  
For patients with immunodeficiencies, there have been only 2 major studies that have 
focused on this population alone. First, Titman et al reported the results of formalized 
neurocognitive testing upon 106 patients with immunodeficiencies. This study showed that 
the underlying genetic disease, presence of ADA deficient SCID and consanguinity were 
associate with a worse outcome. Age at transplantation (<  3 years of age versus > 3 years of 
age), length of stay in the hospital, and chemotherapy conditioning regimen were not 
significant factors (Titman, 2008). 
Lin et al performed a prospective study on the neurocognitive function of 16 patients with 
SCID. Although there were significant decreases in the formal neurocognitive test scores, 
the results showed that these children did learn and acquire developmental milestones, but 
at a slower rate than their age matched normal peers. There was no impact of age (< 8 
months versus > 8 months of age), presence of serious infections prior to HSCT, or length of 
stay in the hospital (Lin, 2009).  
8. Conclusion 
Patients who receive HSCT are at great risk of developing neurological sequelae due to 
either their primary disease, the therapies used to treat the disease and the complications of 
these treatments. The complications can be hard to diagnose. These complications can have 
serious implications for the long-term survivor of HSCT. Formal testing of HSCT recipients 
neurocognitive function should be required for patients  
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